FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds

AdComBPC-157Positive

AI Analysis

Summary

An FDA Advisory Panel voted 8-6-1 in July 2026 to recommend BPC-157 for inclusion on the 503A bulks list, though the recommendation is non-binding and FDA staff opposed the inclusion. A 2025 systematic review identified 35 preclinical studies and one clinical study relevant to the evaluation.

Outcome Details

Advisory panel voted 8-6-1 to back BPC-157 for 503A bulks list inclusion; recommendation is non-binding and does not constitute FDA approval; FDA staff proposed against inclusion

Importance:5/10

Sentiment:

0.30

BPC-157503A BulksFDA Advisory PanelNon-binding RecommendationRegulatory

Read the original article

Published by PR Newswire Clinical Trials on September 8, 2026 6:34 PM

Read Original